Upnorth Investment Ltd 4

4 · TCR2 THERAPEUTICS INC. · Filed Feb 21, 2019

Form 4Exit

Period: 2019-02-19

10% Owner

Transactions

Conversion
Common Stock
[F1][F2]
2019-02-19+322,902→ 322,902 total(indirect: By Upnorth Investment Limited)
Conversion
Common Stock
[F3][F2]
2019-02-19+1,614,517→ 1,937,419 total(indirect: By Upnorth Investment Limited)
Purchase
Common Stock
[F2]
2019-02-19$15.00/sh+200,000$3,000,000→ 2,137,419 total(indirect: By Upnorth Investment Limited)
Conversion
Series A Preferred Stock
[F1][F2]
2019-02-19−2,000,000→ 0 total(indirect: By Upnorth Investment Limited)
→ Common Stock (322,902 underlying)
Conversion
Series B Preferred Stock
[F3][F2]
2019-02-19−10,000,000→ 0 total(indirect: By Upnorth Investment Limited)
→ Common Stock (1,614,517 underlying)

Footnotes (3)

[F1]Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
[F2]The reported securities are owned directly by Upnorth Investment Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
[F3]Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.

Documents

1 file